Webinar: Update on USP Tests for Elemental Impurities

Published: 25-May-2016

Lucideon, a provider of QC testing and method development, is running a free webinar on 7 June


Lucideon, a provider of QC testing and method development, is running a free webinar on 7 June. The webinar, which takes place at 3pm (UK time) and 10am (EST) will cover the replacement to the Heavy Metals limit test <231>, chapters <232> and <233>, looking at categories of elements and analytical challenges.

Topics covered will include:

  • Origin of the limits in chapter <232>
  • Categories of elements in chapter <232>
  • PDE limits for each element and how to calculate the limit in sample
  • Other considerations
  • Analytical challenges in chapter <233>

This webinar will be of interest to anyone who requires testing of pharmaceutical products and/or of dietary supplements; particularly those who currently have the heavy metals test.

To register, click here.

  • Companies:
  • Lucideon
See more

You may also like

Drug Delivery

SkyePharma signs exclusive licensing agreement to access Lucideon’s abuse deterrent drug delivery technology

Read more
First product to be developed for the growing $11bn US opioid market

Trending Articles

  1. LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
  2. Fasenra for EGPA: addressing unmet needs Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
  3. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  4. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  5. Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Drug Delivery

SkyePharma signs exclusive licensing agreement to access Lucideon’s abuse deterrent drug delivery technology

First product to be developed for the growing $11bn US opioid market
You need to be a subscriber to read this article.
Click here to find out more.
Drug Delivery

Advancing controlled release: from polymers to inorganics

Advanced drug delivery systems that provide improved control over active ingredient release have become a focus for research. Aia Malik and Mark Cresswell, from Lucideon, explore the use of polymers and inorganic materials for advanced controlled release systems
Drug Delivery

Lucideon to host ‘Sampling Best Practice for Improved Business Performance’ webinar

Event will take place on Tuesday 20 October 2015 at 2pm (UK time)
Ingredients

Lucideon publishes White Paper on pharmaceutical abuse deterrence

The authors explore the current crisis surrounding prescription drug abuse and the available technologies that are currently helping to combat this issue, as well as the potential solutions of future technologies
Analysis

Lucideon publishes new testing brochure

Capabilities range from materials characterisation, performance testing and regulatory testing through to quality control and failure analysis
Manufacturing

Lucideon releases new healthcare video

Employees from Lucideon’s sites in both the UK and the US talk about how their materials expertise, cross-industry knowledge and quality and accuracy of service add value to the partnerships they build with clients
Research & Development

Lucideon and partners awarded €3.9m grant to train PhD researchers to develop antibacterial medical materials

Four-year project will engage 15 researchers to create and implement new strategies to combat bacteria
Subscribe now